Download ONCOassist App V. 9.23.1
Apple AppStore - Google Play
ONCOassist App V. 9.23.1
by Portable Medical Technology Ltd
Please note: This application, as a decision-support aid, is to be used  by a practicing healthcare professional(“HCP”) and does not replace clinical judgement. It is not designed for use by pati - More Info...

Available Since: 2017-08-09
Developer: Portable Medical Technology Ltd
Seller: Portable Medical Technology Ltd
Price: 0 USD
Current version: 9.23.1
Last Updated: 2025-10-30

Ratings: 4.85 out of 5 stars.
Based on 108 reviews. (Rate/Review)
Genre: Medical
Filesize: 195.29MB
IOS Bundle ID: Portablemed.ONCOassist
Age Rating: 17+
Languages: EN

Videos: ONCOassist App Videos

Please note: This application, as a decision-support aid, is to be used  by a practicing healthcare professional(“HCP”) and does not replace clinical judgement. It is not designed for use by patients and does not replace the advice of a doctor.

ONCOassist is a comprehensive suite of decision support tools developed by oncology professionals, for oncology professionals. It includes a range of breakthrough tools designed to manage patient care effectively. Let's take a closer look at some of the features available:

• NCCN Treatment Protocols: Developed in collaboration with the NCCN, this tool provides information on regimens taken from the NCCN template database.

• Adjuvant Tools: These tools offer 5 and 10-year overall survival rates for patients with and without chemotherapy in an adjuvant setting. Breast cancer, colon cancer, and GIST tools are among the many adjuvant decision support tools available.

• Useful formulas: Body Surface Area, Chemotherapy Dose Calculator, QTc, ECOG Performance Score, Khorana Score, MASCC Risk Index, and many more are included. These calculators simplify medical calculations and include frequently needed conversions and dosage calculations.

• Common Toxicity Criteria for Adverse Events (CTCAE v4.0 & 5.0): This tool provides a standardized classification of adverse effects of drugs used in cancer therapy. CTCAE versions 5.0 and 4.0 are available in an easy-to-use and interactive format.

• AJCC TNM staging: The tool provides criteria for every malignancy and includes the AJCC 7th, 8th, and 9th edition staging criteria.

• Prognostic Scores: This tool offers over 17 prognostic scores for a range of specialties. It helps with prognostication, risk stratification, and determining eligibility for specific treatments or clinical trials.

• Drug info section: Over 200 oncology drugs are available in an easy-to-use and interactive format.

• Drug interaction checker: This tool helps users quickly check for potential drug interactions.

• IO toxicity management tool: This tool is designed to manage immune-related adverse events.

• ONCOnews: From breaking news to in-depth analysis, ONCOnews brings together all oncology news sources in one place.

• ONCOvideos: This offers access to the most recent videos from Oncology Spotlight, which provides insights into the experiences of oncology professionals. Additionally, users can watch OncoAlert and Oncology Brother videos.

ONCOassist offers oncology professionals the following benefits:

Saves Time
Oncology professionals no longer waste time searching through the internet for safe validated information to aid them with their decision making, all of the tools and information they need is available within ONCOassist and is available without the need for internet access.

Improves quality of care
ONCOassist promotes the use of evidence-based medicine. It is also the only CE approved oncology app on the market.

Helps Empower Patients
Adjuvant decision support tools contain patient-friendly information to allow for a more collaborative decision-making process.

Regularly updating
ONCOassist will be updated regularly with new prognostic tools and calculators. We will listen to your feedback and update accordingly. Email us at any time using [email protected].

ONCOassist is regulated by the Irish Health Products Regulatory Authority and is CE marked for conformance as a medical device.

Want BIG updates? Enter your email address:

Delivered Once Every Tuesday.